CommercialCoverageMedium impact
08.01.62g, Nivolumab (Opdivo®), Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 23, 2026
We identified it
Jun 19, 2026
Summary
Insurance policy for Nivolumab (Opdivo) and Nivolumab with Hyaluronidase-nvhy (Opdivo Qvantig) has been updated with revised medical necessity criteria and general guidelines. This affects coverage requirements for these oncology medications used in cancer treatment.
Action Required
Before March 23, 2026: Billing team and oncology providers must review updated medical necessity criteria for Nivolumab (Opdivo) and Opdivo Qvantig claims. Update prior authorization procedures and documentation requirements in billing system. Ensure all future claims meet new medical necessity guidelines to prevent denials.